← All trials
NCT05363644
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- May 6, 2022
- Last posted
- Sep 2, 2022
- Enrollment
- 0
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Advent HealthLead sponsor
- Advent HealthOverall official - principal investigator
- Advent HealthReponsible party - principal investigator
- Integra LifeSciences CorporationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.